|Description||An antiandrogen with about the same potency as cyproterone in rodent and canine species.|
|DrugBank||Primary Accession Number: DB00499|
|Type||Approved, Small Molecule|
|Indication||For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate|
|Mechanism of Action||Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.|
|Absorption||Rapidly and completely absorbed|
|Toxicity||In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia.|
You need to load/activate the cURL extension (http://www.php.net/cURL).